Emerging drugs for neuropathic pain

Expert Opinion on Emerging Drugs

Volumn 6, Issue 2, 2001, Pages 249-259

  Wallace, Mark S ^a  

^a University of California   (United States)

Author keywords

Drug; Neuropathic; Pain; Therapy

Indexed keywords

4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BW 4030W92; CALCIUM ANTAGONIST; CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; DEXMEDETOMIDINE; KETOROLAC; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPEPTIDE ANTAGONIST; NICOTINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; OPIATE; PROSAPOSIN; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SNX 239; SODIUM CHANNEL BLOCKING AGENT; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL MODEL; CHRONIC PAIN; DRUG EFFICACY; GENE EXPRESSION; MOLECULAR GENETICS; MORBIDITY; NERVE INJURY; NEUROPATHY; NOCICEPTION; PAIN ASSESSMENT; PAIN RECEPTOR; PATHOPHYSIOLOGY; RECEPTOR AFFINITY; REVIEW; TISSUE INJURY;

EID: 0035493819     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.6.2.249     Document Type: Review

References (103)

1. Down regulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury
2. Na channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation
3. Sodium channel accumulation in humans with painful neuromas
4. Mexiletine for treatment of chronic painful diabetic neuropathy
5. Mexiletine in the treatment of diabetic neuropathy
6. 200mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomised, double-blind, placebo controlled trial
7. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons
8. Pharmacology of tactile allodynia in the streptozotocin diabetic rat
9. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics
10. A comparison of intrathecally administered narcotic and nonnarcotic analgesics for experimental chronic neuropathic pain
11. Spinal pharmacology of thermal hyperesthesia induced by incomplete ligation of sciatic nerve I opioid and nonopioid receptors
12. Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model
13. Morphine insensitive allodynia is produced by intrathecal strychnine in the lightly anesthetized rat
14. Systemic mexiletine relieves chronic allodynia-like symptoms in rats with ischemic spinal cord injury
15. Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: Effects of modulatory receptor systems and excitatory amino acid antagonists
16. Reversal of nerve ligation-induced allodynia by spinal alpha-2 adrenoreceptor agonists
17. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy
18. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus
19. Gabapentin for the treatment of postherapeutic neuralgia: A randomized controlled trial
20. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood
21. Efficacy of desipramine in painful diabetic neuropathy, a placebo controlled trial
22. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage enrichment design
23. Glutamate receptors in the mammalian central nervous system
24. N-Methyl-D-aspartate receptor-mediate changes in thermal nociception: Allosteric modulation at glycine and polyamine recognition sites
25. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist N-methyl-D-aspartate receptor Gv196771a
26. Modulation of nociceptive transmission by NMDA/glycine site receptor in the ventroposterolateral nucleus of the thalamus
27. The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization
28. Antinociceptive effect of mexiletine in diabetic mice
29. The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneous active fibers originating in rat sciatic neuromas
30. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain
31. Effects of guanethidine on sensitization to natural stimuli and self-mutilating behaviour in rats with a peripheral neuropathy
32. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: Results from a double-blind placebo controlled crossover trial
33. Lamotrigine for pain with hyperalgesia
34. The use of lamotrigine in neuropathic pain
35. Lamotrigine control of central pain
36. + channels in rat sensory neurones by 4030w92, a new antihyperalgesic agent
37. The effect of the novel sodium channel blocker 4030w92, in models of acute and chronic inflammatory pain
38. The effect of 4030w92, a novel sodium channel blocker on the treatment of neuropathic pain in the rat
39. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia
40. Classes of calcium channels in vertebrate cells
41. Calcium channels in vertebrate cells
42. Do calcium channel classifications account for neuronal calcium channel diversity?
43. The central role of voltage-activated and receptor-operated calcium channels in neuronal cells
44. Calcium channel diversity and neurotransmitter release: The W-Conotoxins and W-Agatoxins
45. 2+ channels in mammalian central neurons
46. Antagonists of neuronal calcium channels: Structure, function, and therapeutic implications
47. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia
48. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (Omega-Conopeptide Mviic)
49. Calcium action in synaptic transmitter release
50. Peptide neurotoxins from fish-hunting cone snails
51. Characterization of two kinds of high-voltage-activated Ca-channel currents in chick sensory neurons, differential sensitivity to dihydropyridines and omega-conotoxin gvia
52. Omega-conotoxin-sensitive voltage-operated calcium channels in vertebrate cells
53. Selective N-type neuronal voltage-sensitive calcium channel blocker, snx-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain
54. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
55. Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat
56. Spinal pharmacology of tactile allodynia in diabetic rats
57. Pharmacology of tactile allodynia in the streptozotocin diabetic rat
58. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats
59. Effect of subcutaneous administration of calcium channel blockers on nerve injury-induced hyperalgesia
60. Selective N-type neuronal voltage-sensitive calcium channel blocker, Snx-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain
61. Chronic, opioid-resistant, neuropathic pain: Marked analgesic efficacy of intrathecal ziconotide
62. Epidural clonidine treatment for refractory reflex sympathetic dystrophy
63. Continuous intrathecal hydromorphoneclonidine and clonidine for intractable cancer pain
64. Epidural clonidine analgesia for intractable cancer pain: Phase I
65. Intrathecal morphine and clonidine in the management of spinal cord injury pain: A case report
66. Long-term intrathecal administration of midazolam and clonidine
67. Epidural clonidine analgesia for intractable cancer pain
68. The role of neuronal nicotinic acetylcholine receptors in antinociception: Effects of Abt-594
69. Cyclo-oxygenase inhibition and the spinal release of prostaglandin e2 and amino acids evoked by paw formalin injection: A mictodialysis study in unanesthetized rats
70. Hyperalgesia mediated by spinal glutamate or substance p receptor blocked by spinal cyclo-oxygenase inhibition
71. Hyperalgesia due to nerve injury: Role of prostaglandins
72. Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report
73. 2, e2 or f2α to conscious mice
74. Characterization of Ep-receptor subtypes involved in allodynia and hyperalgesia induced by intrathecal administration of prostaglandin E2 to mice
75. Effect of spinal cord stimulation on tactile hypersensitivity in mononeuropathic rats is potentiated by simultaneous GABA(b) and adenosine receptor activation
76. Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists
77. Exogenous and endogenous adenosine enhance the spinal antialldynic effects of morphine in a rat model of neuropathic pain
78. Reduced anti-allodynic effect of the adenosine a1-receptor agonist R-phenylisopropyladenosine on repeated intrathecal administration and lack of cross-tolerance with morphine in a rat model of central pain
79. Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain
80. Systemic adenosine infusion: A new treatment modality to alleviate neuropathic pain
81. An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection
82. The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain
83. Intrathecal substance P and somtostatin in rats: Behaviour indicative of sensation
84. Behavioural effects of receptor-specific substance P agonists
85. Chemical activation of nociceptive petipheral neurons
86. Prosaptide prevents paclitaxel neurotoxicity
87. Prosaptide prevents hyperalgesia and reduces peripheral tnfr1 expression following TNF-alpha nerve injection
88. Reversal of thermal hyperalgesia in a rat partial sciatic nerve ligation model by prosaptide Tx14(a)
89. 5 reverses hyperalgesia: Inhibition of calcium channels through a pertussis toxin-sensitive G-protein mechanism in the rat
90. Effects of intrathecal vs. systemic clonidine in treating chronic allodynia-like response in spinally injured rats
91. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat
92. Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviours in a rat model of peripheral mononeuropathy
93. Systemic excitatory amino acid receptor antagonists of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and the N-methyl-D-aspartate (NMDA) receptor relieve mechanical hypersensitivity after transient spinal cord ischemia in rats
94. Morphine insensitive allodynia is produced by intrathecal strychnine in the lightly anesthetized rat
95. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: A double-blind comparison to alfentanil and placebo
96. N of 1 randomized controlled trials of oral ketamine in patients with chronic pain
97. Relief of postherpetic neuralgia with the N-methyl-aspartic acid receptor an tagonist ketamine: A double-blind cross-over comparison with morphine, and placebo
98. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia
99. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia
100. Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome Types I and II
101. Mexiletine for thalamic pain syndrome
102. Effect of mexiletine on spinal cord injury dysesthetic pain
103. Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy